Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity

Treatment of cancer with poly (ADP-ribose) polymerase (PARP) inhibitors is currently limited to cells defective in the homologous recombination (HR) pathway. Identification of genetic targets that induce or mimic HR deficiencies will extend the clinical utility of PARP inhibitors. Here we perform a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Pingping, De Souza, Cristabelle, Minn, Kay, Chien, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733792/
https://www.ncbi.nlm.nih.gov/pubmed/31508509
http://dx.doi.org/10.1038/s42003-019-0580-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733792/
https://www.ncbi.nlm.nih.gov/pubmed/31508509
http://dx.doi.org/10.1038/s42003-019-0580-6

Ejemplares similares